MediPharm Labs Corp. subsidiary, MediPharm Labs Australia, has received its cannabis manufacturing licence from the Australian Office of Drug Control under the Narcotics Drugs Act 1967 on May 21, 2019. "This is a significant milestone for MediPharm Labs that establishes the Company as an early mover in the Australian cannabis industry. In addition, MediPharm Labs Australia is expected to provide the Company with a global supply chain platform and a foothold in the Asia-Pacific region," the team with company says.
“With this licence, MediPharm Labs Australia provides a foothold in the Asia-Pacific region as we focus on completing construction, and beginning the facility’s GMP certification and remaining licensing requirements which will permit us to commence production and sales later this year.”
“After starting on this journey nearly two years ago, we are extremely pleased to have been awarded a Medicinal Cannabis Manufacturing Licence from the Office of Drug Control,” says Warren Everitt, Managing Director, MediPharm Labs Australia. “Construction on the facility is well underway and we are one step closer to becoming a leading producer of cannabis concentrates for Australia and the Asia-Pacific region.”
According to the company, the licence authorizes MediPharm Labs Australia to the manufacture extracts and tinctures of cannabis and cannabis resin under the Narcotics Drugs Act 1967. Products manufactured under the Licence must be only for the purpose of a clinical trial or prescribed as medicinal cannabis products.
"MediPharm Labs Australia continues to work on completing the build of a facility in Wonthaggi, Victoria (132 km south east of Melbourne), for industrial-scale production supported by leading infrastructure designed with ISO standard-built cleanrooms and critical environments, considering global GMP workflow," the company continues. "The facility will be outfitted with CO2 extraction capacity to process up to 75,000 kg of dried cannabis annually as well as state-of-the-art secondary processing equipment for the manufacture of purified and high-concentrate cannabis distillate. MediPharm Labs Australia will be permitted to commence production and sales activities upon receipt of its GMP and certain other local licences expected later this year."
For more information:
151 John Street, Barrie
+1 705 719 7425